Literature DB >> 32718537

Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Mutant NSCLC.

Huaqiang Zhou1, Jiayi Shen2, Jiaqing Liu3, Wenfeng Fang4, Li Zhang5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32718537     DOI： 10.1016/j.jtho.2020.03.030

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

Review 1.  Perspectives and Issues in the Assessment of SMARCA4 Deficiency in the Management of Lung Cancer Patients.

Authors:  Subasri Armon; Paul Hofman; Marius Ilié
Journal:  Cells       Date:  2021-07-29       Impact factor: 6.600

2.  Positive outcome of first-line therapy for a SMARCA4-deficient thoracic sarcomatoid tumor.

Authors:  Shigeru Tanaka; Shuhei Hayashi; Yoshitaka Isobe; Eiichi Maruyama; Hiroaki Ozawa; Motoyasu Okuno; Masaru Kondo
Journal:  Int Cancer Conf J       Date:  2021-02-18

3.  A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers.

Authors:  Ling Peng; Jisheng Li; Jie Wu; Bin Xu; Zhiqiang Wang; Georgios Giamas; Justin Stebbing; Zhentao Yu
Journal:  Front Immunol       Date:  2021-10-04       Impact factor: 7.561

Review 4.  Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?

Authors:  Laura Bonanno; Alessandro Dal Maso; Alberto Pavan; Elisabetta Zulato; Lorenzo Calvetti; Giulia Pasello; Valentina Guarneri; PierFranco Conte; Stefano Indraccolo
Journal:  Br J Cancer       Date:  2022-03-09       Impact factor: 9.075

5.  Case Report: A Durable Response to Camrelizumab and Apatinib Combination Therapy in a Heavily Treated Small Cell Carcinoma of the Ovary, Hypercalcemic Type.

Authors:  Guiling Li; Yao Jiang
Journal:  Front Oncol       Date:  2022-07-12       Impact factor: 5.738
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.